Recent Updates
Recently added Catalysts

Pluri Inc.

PLURFDA catalysts, PDUFA dates & pipeline intelligence
$0.94
▼ -0.03 · -3.07%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full PLUR financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.8552W HIGH $3.94
Volume
25.87 K
Value Traded
25.27 K
Short % Float
0.81%
Days to Cover
1.0
-10.48%Week
-10.48%1 Month
-45.03%3 Month
-60.4%6 Month
-75.9%1 Year
-99.85%All Time

Cash Data

Unlock PLUR cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
13.51 M
EPS (TTM)
-2.66
P/E Ratio
-
Ent. Value
33.36 M
Total Shares
14.38 M
Float Shares
9.49 M
Insiders
33.96%
Institutions
18.11%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every PLUR catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

PLUR Catalyst Timeline

Dated clinical, regulatory and corporate events for Pluri Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Pluri Inc.

769Total events
5Upcoming
161Tier-1 (high impact)
2009 to 2027Coverage

Upcoming catalysts 2

T3Manufacturing Milestone
Subscribe to view catalyst details
T2Timing Guidance
Subscribe to view catalyst details
PLX-PAD

Event history 50

●Quarterly UpdateCorporate
Pluri publishes first-quarter fiscal 2027 results
▲Manufacturing MilestoneCMC / Inspection
PluriCDMO obtained ISO 9001:2015 certification for its quality management system
▲Debt Royalty FinancingCorporate
Entity owned by Chairman acquires Pluri's European Investment Bank loan; Pluri released from EIB obligations
●R&D DayPresentation
Pluri holds investor update
▲Partnership / LicenseCorporate
Pluri signs strategic agreement with ZEO ScientifiX for U.S. regenerative medicine expansion
▲Partnership / LicenseCorporate
Pluri and ZEO ScientifiX sign definitive strategic Partnership Agreement for U.S. regenerative medicine manufacturing and commercial platform
▲Corporate ApprovalCorporate
Special independent committee and Board approve EIB loan assignment
▲Partnership / LicenseCorporate
Chairman Alejandro Weinstein agrees to acquire Pluri's EIB loan
◆Equity OfferingCorporate
Closing of offering expected on or about August 28, 2026
▼Equity OfferingCorporate
Pricing of $3.3 million registered direct offering and concurrent private placement
Unlock the full PLUR catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How PLUR actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all PLUR historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 74%
Micro Cap
(rank 532 of 719)
Percentile Rank
Showing 1 of 6 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
PLX-PAD BiologicsCompletedNCT03006770Critical Limb Ischemia (CLI)Phase 3 COMPLETED 213Apr 20, 2022
Unlock the PLUR pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every PLUR program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
PLX-PAD muscle injury following arthroplasty for hip fracturePhase 32022-07-133.2kg from reference (week 6) to week 26 compared to 1.3kg in the placebo group, a 2kg difference (p=0.047); 5.01kg from reference (week 6) to week 52 compared to 0.86kg in the placebo group, a 4kg difference (p=0.0022); 2.3kg from reference (week 6) to week 26 compared to 0.51kg in the placebo group, a 1.8kg difference (p=0.073); 3.3kg from reference (week 6) to week 52 compared to a decrease of 0.7kg in the placebo group, a 4kg difference (p=0.0046); 296 meters versus only 266 meters in placebo treated patients in the 6-minute walk testRead MorePluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture SurgeryRead More
Scroll for more · summaries link to the source press release
Unlock every PLUR trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock PLUR insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Manieu Alexandre WeinsteinDirector, 10% OwnerBuyOffering 833,334 2,083,334 held$1.50 10/23/2026
Unlock the full PLUR insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in PLUR for Q3 2026.
Unlock every fund holding PLUR
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in PLUR
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see PLUR ownership
Insider and institutional ownership, quarter by quarter.

PLUR Short Interest

Shares sold short, counted twice a month.

0.81%
Short % of Float
of tradable shares sold short
76.8K
Shares Sold Short
+265.2% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
97.3K
Avg Daily Volume
the average used for days to cover
Unlock PLUR short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock PLUR option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live PLUR option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock PLUR options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How PLUR ranks across every disease it competes in

Competitive Position is a premium feature
See how PLUR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

PLUR News

PLUR
Nov 16, 2026
PLURGeneral

Pluri CEO Letter: Turning Our Cell Technology and Experience into Commercial Opportunity

Pluri Inc. is advancing its commercial strategy by leveraging over two decades of cell technology and clinical experience. The company has formed a strategic partnership with ZEO ScientifiX to penetrate the U.S. regenerative medicine market. Additionally, Pluri has successfully completed a Phase I clinical trial for PLX-PAD cells and has improved its financial position by transferring its European Investment Bank loan.

Read more →
PLUR
Nov 9, 2026
PLURGeneral

Pluri Adds ISO 9001 and ISO 13485 Certifications to Support PluriCDMO Commercial Expansion

Pluri Inc. announced that its PluriCDMO business has received ISO 9001:2015 and ISO 13485:2016 certifications. These certifications will enhance its quality management systems and support its efforts to engage more customers in the life sciences sector. CEO Yaky Yanay emphasized the importance of quality systems for customer partnerships.

Read more →
PLUR
Oct 27, 2026
PLURConferences/Events
▲ +6.2%on this news

Pluri to Host Investor Conference Calls to Discuss Updates and Strategic Developments

Pluri Inc. will host online investor conference calls on October 29, 2026. CEO Yaky Yanay and Chairman Alejandro Weinstein will provide updates on company developments. The sessions will be conducted in Hebrew at 11 am Israel time and in English at 8:30 am Eastern Time.

Read more →
PLUR
Oct 26, 2026
PLURGeneral
▲ +13.1%on this newsshared move

Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine

Pluri Inc. and ZEO ScientifiX have formed a strategic partnership to enhance U.S. manufacturing and commercialization in regenerative medicine. ZEO contributes its established biologics business and physician relationships, while Pluri offers its expertise in cell-based product development. The collaboration aims to broaden product offerings and strengthen clinical programs, with Pluri acquiring 50% ownership of ZEO.

Read more →
PLUR
Oct 21, 2026
PLURGeneral
▲ +16.7%on this newsshared move

Pluri Chairman and Active Investor Alejandro Weinstein to Acquire EIB Loan, in Strong Vote of Confidence in the Company

Pluri Inc. announced that Chairman Alejandro Weinstein will acquire its loan from the European Investment Bank. This move transfers a significant financial obligation to Weinstein, allowing Pluri to negotiate revised loan terms. Weinstein expressed confidence in Pluri's technology and future, emphasizing this as a step towards reshaping the company for growth in regenerative medicine.

Read more →
PLUR
Aug 27, 2026
PLURGeneral

Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor

Pluri Inc. has announced a registered direct offering and concurrent private placement, raising approximately $3.3 million by selling 2,228,940 common shares at $1.50 each. The offering is expected to close on August 28, 2026, and proceeds will be used for working capital. The company is also issuing unregistered warrants with an exercise price of $1.65.

Read more →
PLUR
Aug 17, 2026
PLURGeneral

Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment

Pluri Inc. announced that its subsidiary, Ever After Foods, has acquired Fishway, a Belgium-based biotechnology company specializing in aquatic cell biology. This acquisition, along with a $2 million strategic investment, aims to enhance Ever After Foods' cultivated-protein platform and expand its capabilities in the European market. The move is expected to strengthen the company's ability to support scalable production for food and ingredient companies.

Read more →
PLUR
Jul 28, 2026
PLURFDA Updates

Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK

Pluri Inc. has announced the successful regulatory registration of its subsidiary Cellav's regenerative aesthetics product, Regenativo+, in the UK. This registration supports the upcoming commercial launch in a market valued at approximately $900 million. The move is part of Pluri's broader strategy to expand its global footprint in regenerative aesthetics and longevity markets, following similar regulatory progress in the U.S.

Read more →
PLUR
Jul 14, 2026
PLURGeneral

Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%

Pluri Inc. Chairman Alejandro Weinstein has invested over $17 million, increasing his ownership to more than 30%. This investment reflects his confidence in Pluri's transition from development to commercial operations, particularly in longevity and tailored biologics. The company is experiencing strong interest from U.S. parties for potential collaborations and product purchases.

Read more →
PLUR
Jun 2, 2026
PLURFDA Updates

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Pluri Inc. has announced the completion of U.S. cosmetic product listings for its regenerative aesthetic products, Regenativo+ and Placento+, through its subsidiary Cellav. The company is preparing for a commercial launch in the U.S. market, which is projected to grow significantly. Clinical validation supports the efficacy of the products, and discussions with distributors are underway. However, the products are not FDA approved and face regulatory requirements.

Read more →
PLUR
Mar 26, 2026
PLURGeneral

Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement

Pluri Inc. announced that Alejandro Weinstein, its Chairman, has made an additional $2.5 million investment at a 30% premium to market price. This follows a previous investment and highlights Weinstein's continued support for the company's growth strategy. The funds from this private placement, amounting to approximately $2.5 million, will be used for general working capital. The transaction involves the sale of common shares and warrants, with an emphasis on enhancing shareholder value through focused execution.

Read more →
PLUR
Feb 18, 2026
PLURGeneral

Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent

Pluri Inc. has been granted a patent by the China National Intellectual Property Administration for its 3D immune cell expansion and activation technology. This patent complements previously secured patents in the U.S., Japan, Korea, Australia, and Israel, strengthening Pluri's global intellectual property portfolio. The technology enables scalable and automated manufacturing of diverse immune cell therapies, positioning Pluri to capitalize on the rapidly growing cell therapy market in China. This strategic expansion is expected to support cross-border partnerships and global collaborations, contributing to the company's efforts in enhancing cost-efficiency and maintaining quality control in cell production.

Read more →
PLUR
Jan 22, 2026
PLURPhases
▲ +9.3%on this news

Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials

Pluri, Inc. has announced the successful completion of the first phase of its program with Resbiomed Technologies, focusing on the production of placenta-derived biomaterials. The collaboration leverages Pluri's proprietary bioprocessing expertise to enhance the quality and scalability of these materials for use in regenerative medicine. Both companies are now prepared to advance to the next phase of the project, which aims to refine manufacturing processes and ensure consistent quality. This milestone underscores the increasing demand for PluriCDMO services in the biotech sector.

Read more →
PLUR
Dec 22, 2025
PLURPhases

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

Pluri, Inc. has expanded its collaboration with Remedy Cell Ltd. by successfully implementing clinical-grade manufacturing processes at Pluri's GMP facility. This achievement includes the completion of engineering runs and the production of clinical-grade batches for Remedy Cell's initial Phase 1b clinical trial, marking significant progress in developing secretome-based therapies for fibrotic diseases. Both companies expressed optimism about their partnership as they aim to provide innovative biotherapeutic solutions to address unmet medical needs.

Read more →
PLUR
Dec 9, 2025
PLURGeneral
▲ +9.9%on this news

Pluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional Investment

Pluri Inc. has appointed Alejandro Weinstein as the new Chairman of the Board, signaling a strategic shift aimed at unlocking value within the company. Weinstein, one of Pluri's largest shareholders, plans to enhance market positioning and realize the potential of Pluri's assets. As part of the leadership transition, outgoing Chairman Zami Aberman will move to the role of Vice Chairman. Additionally, Pluri has entered a private placement agreement to raise approximately $2.5 million to support its operations.

Read more →
PLUR
Nov 13, 2025
PLURGeneral
▼ -6.1%on this news· ran to -18% by day 3

Pluri and Subsidiaries Earn Multiple Industry Honors, Named as Overall BioAgriculture Company of the Year

Pluri Inc. has received multiple industry honors, including the title of Overall BioAgriculture Company of the Year from the Biotech Breakthrough Awards. Additionally, its subsidiaries Coffeesai Ltd. and Kokomodo Ltd. garnered significant recognition for innovations in sustainable food production and cellular agriculture technology, respectively. Pluri's CEO, Yaky Yanay, is set to accept the 2024 Egalitarian Employment Award on behalf of the company. These accolades highlight Pluri's strong position in the biotechnology sector and its commitment to developing impactful cell-based solutions.

Read more →
PLUR
Nov 11, 2025
PLURGeneral
▲ +6.2%on this newsshared move

Pluri Partners with Miss Universe Skincare Introducing Exosome-Enhanced Regenerative Skincare

Pluri Inc. has launched Cellav Health and Aesthetics Ltd., a wholly-owned subsidiary focused on regenerative skincare, following a partnership with Miss Universe Skincare. This collaboration aims to co-develop advanced skincare products utilizing Pluri's proprietary 3D cell expansion technology and is expected to launch its first product in 2026. The partnership is set to leverage Miss Universe Skincare's global distribution network, reaching a market projected to grow significantly in the coming years. This move aligns with Pluri's strategy to expand into high-demand, revenue-generating markets.

Read more →
PLUR
Nov 10, 2025
PLURGeneral
▲ +18.5%on this newsshared move

Leading Global Players Back and Fund Pluri’s Cell-Based Food and Agriculture Collaborations

Pluri, Inc. has entered significant collaborations across Asia, Europe, and the U.S. through its subsidiaries, aiming to innovate food and agriculture production with advanced cell expansion technologies. These partnerships are designed to enhance market presence in cultivated meat, cacao, and coffee industries, reflecting a growing demand for sustainable solutions. Each collaboration includes a proof-of-concept funded by global partners, indicating strong confidence in Pluri's technology.

Read more →
PLUR
Oct 8, 2025
PLURGeneral
▼ -5.1%on this news

Pluri Subsidiary Coffeesai and Instituto del Café de Chiapas Announce Strategic Collaboration to Advance Cell-Based Coffee Manufacturing in Mexico

Pluri Inc.'s subsidiary Coffeesai has partnered with the Instituto del Café de Chiapas to advance cell-based coffee manufacturing in Mexico. The collaboration outlines a three-phase roadmap focusing on cell line development, pilot-scale biofarming, and commercial-scale production. This initiative aims to leverage innovative biotechnology to create sustainable coffee solutions while addressing market demands and environmental challenges.

Read more →
PLUR
May 15, 2025
PLURGeneral

Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion

Pluri Inc. has reported significant growth in revenue, with nearly 400% increase in the first nine months of fiscal year 2025 compared to the previous year. The company is strategically entering the cultivated cacao and coffee markets, addressing global supply challenges. Additionally, Pluri is pursuing partnerships and has received further funding to support its initiatives in healthcare and AgTech. The CEO's letter emphasizes continued expansion efforts and the potential of its proprietary cell expansion technology.

Read more →

About Pluri Inc.

Matam Advanced Technology Park, HAIFA 113 employees pluri-biotech.com
HeadquartersMATAM ADVANCED TECHNOLOGY PARK, HAIFA
BIOPHARMAWATCH ELITE
Trade the next PLUR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime